ArticleFrontiers in immunology2026
Identification and validation of parthanatos-related genes in lung adenocarcinoma and construction of a prognostic risk model.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: As a major cause of cancer-related death, lung adenocarcinoma (LUAD) remains a significant health challenge. Parthanatos plays a crucial role in tumor progression, influencing cancer cell survival and therapy resistance. This study constructed a parthanatos-based prognostic model and explored its associated biological processes. Methods: Data on LUAD transcriptomics and parthanatos-related genes were collected from publicly databases and related literature. Differential expression analysis and weighted gene co-expression network analysis were employed to identify candidate genes. Univariate Cox regression analysis and machine learning algorithms were employed to screen prognostic genes and construct the risk model. Gene expression patterns and intercellular communication within distinct cell types were explored by single-cell sequencing. Lastly, prognostic gene expression in tissue samples was verified by reverse transcription quantitative polymerase chain reaction (RT-qPCR) and western blotting. Results: Conclusion: This study constructed and validated a risk model for LUAD associated with parthanatos, providing new insights into the pathological mechanisms of LUAD and highlighting potential therapeutic targets.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.